French biotech Corteria secures $70M to revive ex-Sanofi heart drugs
Investors are pumping $70 million into a Paris-based biotech’s attempt to revive two of Sanofi’s former cardiovascular programs.
Corteria Pharmaceuticals, founded in 2021, on Thursday unveiled a €65 million ($70.7 million) Series A round co-led by OrbiMed and Jeito Capital that aims to advance a series of heart drugs into the clinic. Founders Philip Janiak and Marie-Laure Ozoux hail from Sanofi, which announced in 2019 that it was dropping cardio and diabetes research.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.